核因子κ-B配體受體致活劑（Receptor activator of nuclear factor kappa-B ligand，RANKL）又稱NF-κB受體激活蛋白配體 [1] ，是一種在人體中由「TNFSF基因」轉譯出來的蛋白質 [2] [3] 。 RANKL為腫瘤壞死因子超家族的一員，屬於第二型穿膜蛋白 [4] 。可以影響免疫系統和調控骨質 ...

核因子κ-B配體受體致活劑（Receptor activator of nuclear factor kappa-B ligand，RANKL）又称NF-κB受体激活蛋白配体 [1] ，是一種在人體中由「TNFSF基因」轉譯出來的蛋白質 [2] [3] 。 RANKL為腫瘤壞死因子超家族的一員，屬於第二型穿膜蛋白 [4] 。可以影響免疫系統和調控骨質 ...

2019年6月19日 · To determine whether AZD4547 can prevent FGF1-induced RANKL/M-CSF expression in osteoblasts, we examined the relative expression levels of Tnfsf11 (encoding Rankl) and Csf1 (encoding M-csf)...

In summary, our data suggest that CD11b promotes RANKL‐induced OC differentiation through the Syk signalling pathway. The high positive rate of CD11b expression in specimens from patients with aseptic loosening indicates the relevance of CD11b expression to …

2024年7月30日 · RANKL（核因子κB配体受体激活剂）和RANK（核因子κB配体受体）是一对在骨代谢中发挥关键作用的信号分子。 在正常情况下，它们调控着骨质的重塑过程，即旧骨的吸收和新骨的形成。 然而，在癌症患者体内，这一通路似乎被“劫持”，成为癌细胞在骨骼中安营扎寨的帮凶。 RANKL-RANK通路与癌症骨转移. 研究发现，某些癌细胞能够分泌RANKL，激活破骨细胞，这些细胞负责吸收骨质。 这不仅导致骨质流失，还为癌细胞提供了更多的空间和养分，促进了 …

2023年9月23日 · 纳鲁索拜单抗是我国原研的全球首个IgG4 RANKL抑制剂，是全人源的IgG4中和性单克隆抗体，铰链区含有两个二硫键，并通过对S228P的突变，防止Fab臂交换，使得构象均一、结构稳定。

TKI 可以进入细胞内, 直接作用于EGFR 家族受体的胞内区, 干扰ATP 结合, 阻断激酶的自身磷酸化, 从而阻断异常的信号传导产生抑瘤效果。 目前FDA 批准上市的药物有 吉非替尼 (gefitinib, Iressa®,2003)、 厄洛替尼 (erlotinib, arceva®, 2004)、 拉帕替尼 (lapatinib, Tykerb®, 2007) 和 阿法替尼 (afatinib,Gilotrif®, 2013)。

核因子κ-B配体受体致活剂（Receptor activator ofnuclear factor kappa-B ligand，RANKL）是肿瘤坏死因子超家族的一员，为破骨细胞分化激活的关键因子，具有诱导破骨细胞生产活化，抑制破骨细胞凋亡的作用，可用于骨质疏松的治疗。

Receptor activator of NF-κB (RANK) ligand (RANKL) induces the differentiation of monocyte/macrophage–lineage cells into the bone–resorbing cells called osteoclasts.

2020年5月13日 · Receptor Activator of NF-κB Ligand (RANKL) is instrumental for the terminal differentiation of myeloid cells into osteoclasts. RANKL binds to its transmembrane receptor RANK and induces intracellular signaling pathways, which include TRAF6 and c-Fos.

2023年7月8日 · 据统计，在中国肺癌患者中，表皮生长因子受体（EGFR）突变率可达 40%-60%，EGFR 酪氨酸激酶抑制剂（TKI）已成为 EGFR 突变阳性的晚期 NSCLC 患者的一线或二线治疗方案。 EGFR-TKI 等靶向治疗药物较化疗选择性高、安全性佳，平衡了有效性、安全性和便利性，广受患者青睐，但它们仍有不少不良反应。 因此，掌握 EGFR-TKI 不良反应管理，积极采取有效措施预防或治疗一代、二代、三代 EGFR-TKI 所致的不良反应，是肿瘤专业临床医生的 …

核因子κ-B配体受体致活剂（Receptor activator of nuclear factor kappa-B ligand，RANKL）又称NF-κB受体激活蛋白配体 [1] ，是一种在人体中由“TNFSF基因”转译出来的蛋白质 [2] [3] 。 RANKL为肿瘤坏死因子超家族的一员，属于第二型穿膜蛋白 [4] 。可以影响免疫系统和调控骨质 ...

4 天之前 · Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 fusion tyrosine kinase have revolutionized the treatment of chronic myeloid leukaemia (CML). However, the development of TKI resistance and ...

2014年5月28日 · Our findings indicate that the tyrosine kinase Lyn is activated when MIF binds to its receptor CD74 and its coreceptor CD44 and, in turn, down-regulates the RANKL-mediated signaling cascade by suppressing NF-ATc1 protein expression through down-regulation of AP-1 and calcium signaling components.

2008年3月7日 · Here we report that mice lacking the tyrosine kinases Btk and Tec show severe osteopetrosis caused by a defect in bone resorption. RANK and ITAM signaling results in formation of a Btk (Tec)/BLNK (SLP-76)-containing complex and PLCγ-mediated activation of an essential calcium signal.

The canonical mechanism for osteoclast differentiation depends on activation of a TNF-family receptor, receptor activator of nuclear factor-κB (RANK) by its ligand, RANKL. Signals from immune-related receptors and activity of CSF-1 (M-CSF) …

In summary, our data suggest that CD11b promotes RANKL-induced OC differentiation through the Syk signalling pathway. The high positive rate of CD11b expression in specimens from patients with aseptic loosening indicates the relevance of CD11b expression to …

RANKL (TNFSF11), a type II transmembrane protein, is a receptor activator of NF-κB (RANK) ligand. RANKL is an activator of RANK. When binding to RANK, it induces the differentiation of monocyte/macrophage-lineage cells into osteoclasts and leads to …

2017年3月13日 · Here, we have provided evidence that RANKL controls the expression of 3BP2, an adapter protein that is required for activation of SRC tyrosine kinase and simultaneously coordinates the attenuation of β-catenin, both of which are required to execute the osteoclast developmental program.

2025年3月13日 · Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the established first-line treatment for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, but survival advantages in advanced-stage cases remain modest and show interpatient variability. This study seeks to delineate real-world survival outcomes in stage IV EGFR-mutant ...